Cardiovascular Clinical Trials

Statistical methods in cardiovascular trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All cardiovascular trials

965 results

• Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert: Complete Statistical AnalysisIndependent statistical analysis of Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01467947).Phase 4Results postedn = 46NCT01467947
• Poststroke Depression in Hemorrhagic Stroke: Complete Statistical AnalysisIndependent statistical analysis of Poststroke Depression in Hemorrhagic Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03826875).Phase 2Results postedn = 8NCT03826875
• Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure: Complete Statistical AnalysisIndependent statistical analysis of Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 3,071NCT02996565
• PrE1003Independent statistical analysis of Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 63NCT00790842
• PRECAFIndependent statistical analysis of Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 35NCT03646643
• PREMIERIndependent statistical analysis of Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 59NCT01004406
• PREMIERIndependent statistical analysis of Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 197NCT02186561
• PRESERVEIndependent statistical analysis of the randomized phase 3 PRESERVE trial evaluating intravenous sodium bicarbonate versus saline and oral N-acetylcysteine versus placebo for serious patient-centered events following angiography.Phase 3Results postedn = 5,177NCT01467466
• PRESERVEIndependent statistical analysis of Prevention of Serious Adverse Events Following Angiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01467466).Phase 3Results postedn = 5,177NCT01467466
• Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04582877).Phase NAResults postedn = 300NCT04582877
• PRESSUREwire Study: Complete Statistical AnalysisIndependent statistical analysis of PRESSUREwire Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02935088).Phase NAResults postedn = 2,217NCT02935088
• PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe): Complete Statistical AnalysisIndependent statistical analysis of PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01238835).Phase NAResults postedn = 220NCT01238835
• PREVENTIndependent statistical analysis of Improving Patient Prioritization During Hospital-homecare Transition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04136951).Phase NAResults postedn = 1,915NCT04136951
• PREVENTIndependent statistical analysis of Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02769338).Phase NAResults postedn = 2,292NCT02769338
• Preventing Sickle Cell Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Preventing Sickle Cell Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02373241).Phase 2Results postedn = 1NCT02373241
• Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 362NCT01278745
• Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 1,084NCT00684307
• PRIMEIndependent statistical analysis of Prospective Research in Infants With Mild Encephalopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01747863).Phase NAResults postedn = 63NCT01747863
• Primed vs. Unprimed rTMS in Chronic Stroke: Complete Statistical AnalysisIndependent statistical analysis of Primed vs. Unprimed rTMS in Chronic Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01757821).Phase NAResults postedn = 11NCT01757821
• PRISMIndependent statistical analysis of Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 85NCT02085551
• PRISMSIndependent statistical analysis of the PRISMS phase 3 trial of alteplase in participants with mild stroke, covering the Day 90 modified Rankin Scale endpoint, risk difference, odds ratios, safety outcomes, trial design,…Phase 3Results postedn = 313NCT02072226
• PRO-HFIndependent statistical analysis of Patient-Reported Outcome Measurement in Heart Failure Clinic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04164004).Phase NAResults postedn = 1,249NCT04164004
• ProBPIndependent statistical analysis of Clinical Trial of Dietary Protein and Blood Pressure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00046566).Phase NAResults postedn = 352NCT00046566
• ProDiuSIndependent statistical analysis of Protocolized Diuretic Strategy in Cardiorenal Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01921829).Phase 4Results postedn = 19NCT01921829
• Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients: Complete Statistical AnalysisIndependent statistical analysis of Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 250NCT00356759
• PROMISEIndependent statistical analysis of Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 30NCT01988246
• Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin): Complete Statistical AnalysisIndependent statistical analysis of Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 263NCT00634907
• PROSPERIndependent statistical analysis of PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01274637).Phase 3Results postedn = 62NCT01274637
• PROTECTED TAVRIndependent statistical analysis of PROTECTED TAVR, a randomized trial evaluating the Sentinel Cerebral Protection System during transcatheter aortic valve replacement and the rate of stroke through 72 hours or discharge.Phase NAResults postedn = 3,000NCT04149535
• PROTECTED TAVRIndependent statistical analysis of PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 3,000NCT04149535
• Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting: Complete Statistical AnalysisIndependent statistical analysis of Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 189NCT01654666
• Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study: Complete Statistical AnalysisIndependent statistical analysis of Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00604383).Phase 3Results postedn = 685NCT00604383
• Protocol1Independent statistical analysis of Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03560323).Phase 1Results postedn = 41NCT03560323
• PULSED AFIndependent statistical analysis of Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04198701).Phase NAResults postedn = 421NCT04198701
• Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea: Complete Statistical AnalysisIndependent statistical analysis of Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 34NCT04153188
• PUMP-ExIndependent statistical analysis of Exercise-primed Upper Extremity Motor Practice in Chronic Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04259424).Phase NAResults postedn = 10NCT04259424
• QUARTO_IIIIndependent statistical analysis of Quartet Lead and Resynchronization Therapy Options III (QUARTO_III): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02476201).Phase NAResults postedn = 105NCT02476201
• QuickOpt Chronic Study: Complete Statistical AnalysisIndependent statistical analysis of QuickOpt Chronic Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01172067).Phase NAResults postedn = 400NCT01172067
• QUORUMIndependent statistical analysis of Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 295NCT03715998
• RAAS and Arterial Stiffness in SCI: Complete Statistical AnalysisIndependent statistical analysis of RAAS and Arterial Stiffness in SCI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04510974).Phase NAResults postedn = 33NCT04510974
• RADAR-AIndependent statistical analysis of Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 19NCT03519347
• RAFAELOCALIndependent statistical analysis of Evaluation of the Value of Perianal Infiltration During Thermodestruction of Haemorrhoidal Disease by Radiofrequency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 134NCT05519189
• Randomized Controlled Trial of Group Prevention Coaching: Complete Statistical AnalysisIndependent statistical analysis of Randomized Controlled Trial of Group Prevention Coaching: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01838226).Phase NAResults postedn = 401NCT01838226
• Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 948NCT01565564
• Rapid Switch From Flolan to Remodulin in the Outpatient Clinic: Complete Statistical AnalysisIndependent statistical analysis of Rapid Switch From Flolan to Remodulin in the Outpatient Clinic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00643604).Phase 4Results postedn = 7NCT00643604
• RasbAKIIndependent statistical analysis of Lowering Serum Uric Acid to Prevent Acute Kidney Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756964).Phase 2Results postedn = 26NCT00756964
• Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02132767).Phase 3Results postedn = 523NCT02132767
• RE-COVER IComplete statistical analysis of RE-COVER I, the randomized phase 3 trial comparing dabigatran 150 mg with warfarin for 6 months in patients with acute symptomatic venous thromboembolism, including non-inferiority methodology, time-to-event analyses,…Phase 3Results postedn = 2,564NCT00291330
• RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: Complete Statistical AnalysisIndependent statistical analysis of RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 7,797NCT02596230
• RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 1,878NCT00621855

← All therapeutic areas